Two Sigma Advisers LP Trims Stock Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Two Sigma Advisers LP reduced its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 12.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 85,900 shares of the company's stock after selling 12,400 shares during the quarter. Two Sigma Advisers LP owned 0.18% of Amphastar Pharmaceuticals worth $3,189,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Tower Research Capital LLC TRC grew its stake in shares of Amphastar Pharmaceuticals by 43.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company's stock valued at $43,000 after purchasing an additional 348 shares during the last quarter. Huntington National Bank grew its stake in shares of Amphastar Pharmaceuticals by 36.9% in the 4th quarter. Huntington National Bank now owns 1,340 shares of the company's stock valued at $50,000 after purchasing an additional 361 shares during the last quarter. Bank of Montreal Can grew its stake in shares of Amphastar Pharmaceuticals by 4.6% in the 4th quarter. Bank of Montreal Can now owns 8,215 shares of the company's stock valued at $305,000 after purchasing an additional 361 shares during the last quarter. TD Private Client Wealth LLC grew its stake in shares of Amphastar Pharmaceuticals by 22.7% in the 4th quarter. TD Private Client Wealth LLC now owns 2,099 shares of the company's stock valued at $78,000 after purchasing an additional 388 shares during the last quarter. Finally, Smartleaf Asset Management LLC grew its stake in shares of Amphastar Pharmaceuticals by 222.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 715 shares of the company's stock valued at $26,000 after purchasing an additional 493 shares during the last quarter. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have recently commented on the company. Wells Fargo & Company reduced their price target on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating for the company in a report on Thursday, May 8th. JPMorgan Chase & Co. reissued a "neutral" rating and issued a $30.00 price target (down from $45.00) on shares of Amphastar Pharmaceuticals in a report on Monday, May 12th. Needham & Company LLC reissued a "hold" rating on shares of Amphastar Pharmaceuticals in a report on Thursday, April 10th. Finally, Piper Sandler reduced their price target on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a report on Friday, March 21st. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, Amphastar Pharmaceuticals has an average rating of "Hold" and a consensus target price of $32.33.

Insider Buying and Selling

In related news, CFO William J. Peters sold 4,231 shares of Amphastar Pharmaceuticals stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total transaction of $116,521.74. Following the completion of the transaction, the chief financial officer now directly owns 97,363 shares of the company's stock, valued at approximately $2,681,377.02. The trade was a 4.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Over the last ninety days, insiders sold 5,231 shares of company stock valued at $142,752. 27.10% of the stock is owned by insiders.

Amphastar Pharmaceuticals Price Performance

AMPH stock traded up $0.24 during midday trading on Friday, hitting $25.88. 460,917 shares of the stock were exchanged, compared to its average volume of 484,740. The stock's 50-day moving average price is $24.92 and its 200-day moving average price is $32.15. The stock has a market cap of $1.23 billion, a price-to-earnings ratio of 8.63, a PEG ratio of 2.19 and a beta of 0.78. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $22.64 and a fifty-two week high of $53.96. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.